METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS
First Claim
1. A method of treating a skin disorder characterized by cutaneous lymphocyte antigen positive T cells in a mammal comprising administering to the mammal a therapeutically effective amount of a neutralizing monoclonal antibody or antibody fragment thereof which specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:
- 2, wherein the skin disorder is pruritis associated with cutaneous T cell lymphoma, and wherein after administration the skin disorder is improved.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
21 Citations
6 Claims
-
1. A method of treating a skin disorder characterized by cutaneous lymphocyte antigen positive T cells in a mammal comprising administering to the mammal a therapeutically effective amount of a neutralizing monoclonal antibody or antibody fragment thereof which specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:
- 2, wherein the skin disorder is pruritis associated with cutaneous T cell lymphoma, and wherein after administration the skin disorder is improved.
- View Dependent Claims (2, 3)
-
4. A method of treating a skin disorder characterized by cutaneous lymphocyte antigen positive T cells in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising a neutralizing monoclonal antibody or antibody fragment thereof and a pharmaceutically acceptable carrier, wherein the neutralizing monoclonal antibody or antibody fragment specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:
- 2, wherein the skin disorder is pruritis associated with cutaneous T cell lymphoma, and wherein after administration the skin disorder is improved.
- View Dependent Claims (5, 6)
Specification